The introduction of mTOR inhibitors (mTORis), such as sirolimus and everolimus, has provided new insights into the management of the tumor-related forms of TSC, significantly improving patient quality of life by controlling tumor growth and reducing systemic complications. This evidence concerns the gene MTOR and neoplasm.